Clinical Trial Update: A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates docetaxel with or without XH1 in non-small cell lung cancer, status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• XH1 (XH1)

Snippet

Sponsor: Haining Health-Coming Biotech Co., Ltd. | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN